Advertisement

Application of Pathological Staging in Esophageal Adenocarcinoma

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1756)

Abstract

Staging is one of the most important factors that determine the prognosis of the patients with esophageal adenocarcinoma. The current staging protocol includes parameters—extent of tumor (T), lymph node status (N), presence of distant metastasis (M), and grade of the adenocarcinoma (G). In addition, different criteria are used in patients with and without neoadjuvant therapy. The silent aspects of the use of new staging protocol are discussed.

Key words

Esophageal adenocarcinoma Staging Pathological Neoadjuvant therapy Grade 

References

  1. 1.
    Denoix PF (1946) Enquete permanent dans les centres anticancereaux. Bull Inst Nat Hyg 1:70–75Google Scholar
  2. 2.
    UICC (1968) TNM pocket book, “the Livre de Poche”, 1st ednGoogle Scholar
  3. 3.
    American Joint Committee for Cancer Staging and end results reporting (1977) Manual for staging of cancer. American Joint Committee for Cancer Staging, Chicago, ILGoogle Scholar
  4. 4.
    UICC (1987) TNM classification, 4th ednGoogle Scholar
  5. 5.
    Beahrs OH, Henson DE, Hutter RVP, Myers MH (eds) (1988) Manual for staging of cancer, 3rd edn. Lippincott, Philadelphia, PAGoogle Scholar
  6. 6.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) Esophagus and esophagogastric junction. In: AJCC cancer staging manual, 7th edn, Part 3. Springer, New York, pp 103–155, Chapter 10Google Scholar
  7. 7.
    Rice TW, Kelsen D, Blackstone E, Ishwaran H, Patil DT, Bass AJ, Erasmus JJ, Gerdes H, Hofstetter WL (2016) Esophagus and esophagogastric junction. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (eds) AJCC cancer staging manual, 8th edn. Springer, New York, pp 185–202. Chapter 16Google Scholar
  8. 8.
    Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Swisher SG, Watson TJ, Blackstone EH (2009) Worldwide esophageal cancer collaboration. Dis Esophagus 22:1–8CrossRefGoogle Scholar
  9. 9.
    Lam AK (2015) Cellular and molecular biology of esophageal cancer. In: Saba NF, El-Rayes BF (eds) Esophageal cancer: prevention, diagnosis and therapy. Springer, New York, pp 25–40. Chapter 2, ISBN: 978-3-319-20068-2CrossRefGoogle Scholar
  10. 10.
    Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Hofstetter WL, Watson TJ, Allen MS, Rusch VW, Blackstone EH (2010) Optimum lymphadenectomy for esophageal cancer. Ann Surg 251:46–50CrossRefGoogle Scholar
  11. 11.
    Chen YJ, Schultheiss TE, Wong JY, Kernstine KH (2009) Impact of the number of resected and involved lymph nodes on esophageal cancer survival. J Surg Oncol 100:127–132CrossRefGoogle Scholar
  12. 12.
    Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248:549–556CrossRefGoogle Scholar
  13. 13.
    Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, Lerut EM, Denlinger CE, Salo JA, Scott WJ, Watson TJ, Allen MS, Chen LQ, Rusch VW, Cerfolio RJ, Luketich JD, Duranceau A, Darling GE, Pera M, Apperson-Hansen C, Blackstone EH (2017) Esophageal cancer: associations with (pN+) lymph node metastases. Ann Surg 265:122–129CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2018

Authors and Affiliations

  1. 1.Cancer Molecular Pathology of School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations